Stockscreener 앱 받기
1.48
0.85%
-0.02
전일 마감가:
$1.50
열려 있는:
$1.51
하루 거래량:
34,378
Relative Volume:
0.18
시가총액:
$72.39M
수익:
$9.16M
순이익/손실:
$-68.17M
주가수익비율:
-0.908
EPS:
-1.63
순현금흐름:
$-80.16M
1주 성능:
+1.87%
1개월 성능:
-7.04%
6개월 성능:
-12.51%
1년 성능:
+10.17%
1일 변동 폭
$1.46
$1.51
1주일 범위
$1.45
$1.53
52주 변동 폭
$1.22
$1.94
아이케나 온콜로지 Stock (IKNA) Company Profile
명칭
Ikena Oncology Inc
전화
857-343-8292
주소
50 NORTHERN AVE., BOSTON
IKNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IKNA
Ikena Oncology Inc
|
1.4796 | 72.39M | 9.16M | -68.17M | -80.16M | -1.63 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.45 | 113.70B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.16 | 75.52B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.74 | 39.78B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.41 | 35.34B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
122.06 | 29.05B | 3.30B | -501.07M | 1.03B | -2.1146 |
아이케나 온콜로지 Stock (IKNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2023-09-22 | 개시 | Wedbush | Outperform |
| 2023-05-04 | 재개 | H.C. Wainwright | Buy |
| 2021-12-23 | 개시 | H.C. Wainwright | Buy |
| 2021-05-05 | 재개 | Credit Suisse | Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-04-20 | 개시 | Credit Suisse | Outperform |
| 2021-04-20 | 개시 | Jefferies | Buy |
| 2021-04-20 | 개시 | William Blair | Outperform |
모두보기
아이케나 온콜로지 주식(IKNA)의 최신 뉴스
Jane Street Group LLC Sells 18,570 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Geode Capital Management LLC Acquires 14,319 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
How former leaders of a sold-off biotech company landed their drugs again - The Business Journals
Deal Watch: Regeneron Quietly Acquires UK Ophthalmology Firm Oxular - Scrip
US Penny Stocks To Watch In January 2025 - Simply Wall St
What Direction Does Ikena Oncology Inc (NASDAQ: IKNA) Analysts Think The Company Will Take? - Stocks Register
Ikena Oncology (IKNA) Moves to Buy: Rationale Behind the Upgrade - MSN
Is Amazon a Buy, Sell, or Hold in 2025? - Yahoo! Voices
Ikena Oncology and Inmagene Biopharmaceuticals to Merger - citybiz
Spruce Biosciences Appoints Interim Chief Medical Officer - MSN
Inmagene takes back-door route to Nasdaq listing - The Pharma Letter
Ikena Oncology, Inc. announced that it expects to receive $75 million in funding from a group of investors - Marketscreener.com
Five things you need to know, and a Chrismukkah throwback - The Business Journals
Mitek Systems (NASDAQ:MITK) Rating Increased to Strong-Buy at StockNews.com - Defense World
Helius Medical Technologies, Inc. Announces First PoNS System Sale to VA Healthcare SystemOn December 23, 2024, Helius Medical Technologies, Inc. (NASDAQ:HSDT) disclosed its successful sale of the first Portable Neuromodulation Stimulator (PoNS) - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Shares Purchased by Fmr LLC - Defense World
What is HC Wainwright’s Forecast for CVE:NDA Q1 Earnings? - Defense World
Ikena Oncology Enters into Merger Agreement with Inmagene BiopharmaceuticalsOn December 23, 2024, Ikena Oncology, Inc. (NASDAQ: IKNA) announced a significant development as it entered into a Merger Agreement with Inmagene Biopharmaceuticals. - Defense World
**FibroBiologics Enters Standby Equity Purchase Agreement for $25 Million Financing** ** - Defense World
Moving iMage Technologies Reports Results of Annual Meeting On December 19, 2024, Moving iMage Technologies, Inc. (NYSEAMERICAN: MITQ) held its annual meeting of stockholders. The company disclosed details regarding the meeting through an 8-K - Defense World
D-Wave Quantum Inc. (NYSE:QBTS) Receives $5.63 Consensus Price Target from Analysts - Defense World
Salesforce (NYSE:CRM) Stock Price Down 0% Following Insider Selling - Defense World
Boston biotech opts for reverse merger with San Diego company - The Business Journals
Ikena Oncology and Inmagene Announce Merger and Fundraising - Yahoo Finance
Ikena Oncology (NASDAQ:IKNA) Receives “Neutral” Rating from Wedbush - Defense World
Ikena Oncology, Inc. announced that it expects to receive $75 million in funding - Marketscreener.com
Ikena Oncology's (IKNA) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
Ikena Oncology Merger with Inmagene Biopharmaceuticals and Private Placement Financing - Leerink Partners
Ikena Oncology Shares Rise After Merger Announcement With Inmagene Biopharmaceuticals - MarketWatch
Ikena Oncology and Inmagene Biopharmaceuticals announces merger - MSN
Ikena Oncology, Inmagene Biopharmaceuticals to Merge - MarketWatch
Bionano Announces Publication from Johns Hopkins School of Medicine Showing that OGM Outperformed Multiple Cytogenetic Assays in a Study of Bone and Soft Tissue Tumor Analysis - The Manila Times
iKena Oncology, Inmagene enter definitive merger agreement, private placement - TipRanks
Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement - GlobeNewswire
Questor Technology (OTCMKTS:QUTIF) Trading Down 13% – Should You Sell? - Defense World
Ikena Oncology, Inc. (NASDAQ:IKNA) Short Interest Update - MarketBeat
How Is Procter & Gamble's Stock Performance Compared to Other Consumer Staples Stocks? - MSN
Ikena Oncology FY2024 EPS Estimate Boosted by HC Wainwright - Defense World
Ikena Oncology FY2024 EPS Forecast Lifted by HC Wainwright - MarketBeat
3 US Penny Stocks With Market Caps Over $40M To Consider - Simply Wall St
Ikena Oncology (NASDAQ:IKNA) Earns “Buy” Rating from HC Wainwright - Defense World
Ikena Oncology (NASDAQ:IKNA) Given "Buy" Rating at HC Wainwright - MarketBeat
Ikena Oncology Third Quarter 2024 Earnings: US$0.21 loss per share (vs US$0.40 loss in 3Q 2023) - Yahoo Finance
Wedbush Reaffirms “Neutral” Rating for Ikena Oncology (NASDAQ:IKNA) - Defense World
Ikena Oncology Reports Strategic Realignment and Financial Performance - TipRanks
Ikena Oncology Reports Third Quarter 2024 Financial Results - GlobeNewswire
Ikena Oncology Reports 41% Lower Net Loss, Strong $138M Cash Position in Q3 | IKNA Stock News - StockTitan
Halcones signs binding deal to buy Chilean gold project - Yahoo News
Renaissance Technologies LLC Sells 300,200 Shares of Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals - Indian Pharma Post
Point72 Asia Singapore Pte. Ltd. Invests $75,000 in Ikena Oncology, Inc. (NASDAQ:IKNA) - Defense World
아이케나 온콜로지 (IKNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.42%
4.93%
자본화:
|
볼륨(24시간):